Skip to main content

David Charles Montefiori, PhD

Professor in Surgery
Office: Surgical Oncology Res Fac, Durham, NC 27710
Campus Mail: DUMC Box 2926 Med Ctr, Durham, NC 27710

Dr. Montefiori is Professor and Director of the Laboratory for AIDS Vaccine Research and Development in the Department of Surgery, Division of Surgical Sciences, Duke University Medical Center. His major research interests are viral immunology and AIDS vaccine development, with a special emphasis on neutralizing antibodies. One of his highest priorities is to identify immunogens that generate broadly cross-reactive neutralizing antibodies for inclusion in HIV vaccines.  Many aspects of the neutralizing antibody response are studied in his laboratory, including mechanisms of neutralization and escape, epitope diversity among genetic subtypes and geographic origins, ontogeny of broadly neutralizing antibody responses and computationally-assisted vaccine design. Over the years he has explored multiple types of assays for neutralizing antibodies and other potential antiviral antibodies, focusing on assay optimization, standardization, validation and high throughput. The scope of research covers HIV-infected individuals and nonhuman primate models of simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection.  Dr. Montefiori also directs a large AIDS vaccine immune monitoring program, which operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate AIDS vaccines since 1988. In 2002 he chaired the Antibody Laboratory Standardization Working Group that assisted in the design of the Global HIV Vaccine Enterprise Strategic Plan for HIV vaccines. He currently directs the Core Neutralizing Antibody Laboratories for the HIV Vaccine Clinical Trials Network (HVTN), the NIH Preclinical HIV-1 Vaccine Program and the Center for HIV/AIDS Vaccine Immunology- Immunogen Design (CHAVI-ID). He also directs a large Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) as part of the Bill and Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD). He has published over 500 original research papers that have helped shape the scientific rationale for antibody-based HIV-1 vaccines.

Education and Training

  • Ph.D., Clemson University, 1982

Selected Grants

Publications

Eslamizar, L., C. Petrovas, D. J. Leggat, K. Furr, M. L. Lifton, G. Levine, S. Ma, et al. “Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center (Accepted).” In Npj Vaccines, Vol. 6, 2021. https://doi.org/10.1038/s41541-020-00277-1.

Full Text

Gorman, Matthew J., Nita Patel, Mimi Guebre-Xabier, Alex L. Zhu, Caroline Atyeo, Krista M. Pullen, Carolin Loos, et al. “Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.” Cell Rep Med 2, no. 9 (September 21, 2021): 100405. https://doi.org/10.1016/j.xcrm.2021.100405.

Full Text

Sholukh, Anton M., Andrew Fiore-Gartland, Emily S. Ford, Maurine D. Miner, Yixuan J. Hou, Longping V. Tse, Hannah Kaiser, et al. “Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays.” J Clin Microbiol 59, no. 10 (September 20, 2021): e0052721. https://doi.org/10.1128/JCM.00527-21.

Full Text

Corbett, Kizzmekia S., Martha C. Nason, Britta Flach, Matthew Gagne, Sarah O’Connell, Timothy S. Johnston, Shruti N. Shah, et al. “Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.” Science 373, no. 6561 (September 17, 2021): eabj0299. https://doi.org/10.1126/science.abj0299.

Full Text

Choi, Angela, Matthew Koch, Kai Wu, Laurence Chu, LingZhi Ma, Anna Hill, Naveen Nunna, et al. “Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.” Nat Med, September 15, 2021. https://doi.org/10.1038/s41591-021-01527-y.

Full Text

Schooten, Jelle van, Marlies M. van Haaren, Hui Li, Laura E. McCoy, Colin Havenar-Daughton, Christopher A. Cottrell, Judith A. Burger, et al. “Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates.” Plos Pathogens 17, no. 8 (August 25, 2021): e1009736. https://doi.org/10.1371/journal.ppat.1009736.

Full Text

Antanasijevic, Aleksandar, Leigh M. Sewall, Christopher A. Cottrell, Diane G. Carnathan, Luis E. Jimenez, Julia T. Ngo, Jennifer B. Silverman, et al. “Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM.” Nature Communications 12, no. 1 (August 10, 2021): 4817. https://doi.org/10.1038/s41467-021-25087-4.

Full Text

Li, Dapeng, Robert J. Edwards, Kartik Manne, David R. Martinez, Alexandra Schäfer, S Munir Alam, Kevin Wiehe, et al. “In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.” Cell 184, no. 16 (August 5, 2021): 4203-4219.e32. https://doi.org/10.1016/j.cell.2021.06.021.

Full Text

Huang, Yunda, Kelly E. Seaton, Martin Casapia, Laura Polakowski, Stephen C. De Rosa, Kristen Cohen, Chenchen Yu, et al. “AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.” Vaccine 39, no. 33 (July 30, 2021): 4641–50. https://doi.org/10.1016/j.vaccine.2021.06.066.

Full Text

Pino, Maria, Talha Abid, Susan Pereira Ribeiro, Venkata Viswanadh Edara, Katharine Floyd, Justin C. Smith, Muhammad Bilal Latif, et al. “A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.” Sci Immunol 6, no. 61 (July 15, 2021). https://doi.org/10.1126/sciimmunol.abh3634.

Full Text

Pages